Cipla Ltd. — Capital/Financing Update 2022

Aug 30, 2022

30th August 2022

(1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001

Scrip Code: 500087

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph 11, L-1840 Luxembourg

National Stock Exchange of India Limited Listing Department Exchange Plaza, 5 th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA EQ

Sub: Intimation under Regulation 30 read with Schedule Ill of SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015

(2)

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") and further to the intimation dated 15th July 2019, we hereby notify that Cipla (EU) Limited, ("Cipla EU"), wholly owned subsidiary of the Company in UK has agreed to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical Co. Ltd., a subsidiary of Cipla EU in China. Post-acquisition, Cipla EU's stake in the subsidiary, will increase to 93.10%.

Requisite details under SEBI Listing Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015dated 9 th September 2015 are enclosed as Annexure - I to this letter.

Please take the above information on record.

Thankyou

Yours faithfully, For Cipla Limited

Rajendra Chopra Company Secretary Prepared by: Simona Dsouza

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Pa rel, Mumbai-400 013, India P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

Annexure-1 Details as per SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015

Sr.	Particulars	Details
No.
a)	Name of the target entity, details in brief such as size, turnover etc.;	Name of the target entity: Cipla (Jiangsu) Pharmaceutical Co. Ltd. ("JV Co.") Brief Details: The JV Co. is a joint venture between Cipla (EU) Limited and Jiangsu XiDi Pharmaceuticals Co., Ltd (formerly known Jiangsu Acebright as Pharmaceuticals Co., Ltd), incorporated in 2019, in China, for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services.
		Turnover: Nil as on 3l51 March 2022 since the JV Co. is yet to commence its operations
b)	Whether the would acquisition fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any	The proposed acquisition is not a related party transaction under the Companies Act, 2013 or IND AS 24.
	interest in the entity being acquired? If nature of interest and yes, details thereof and whether the same is done at " arm' s length";	For the limited purpose of Listing Regulations, the transaction is a related party transaction and will be at arm' s length.
		of the promoter/promoter None group/group companies have any interest in the entity.
c)	Industry to which the entity being acquired belongs;	Pharmaceutical Industry
d)	of Objects and effects acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To provide quality drugs and strengthen presence in China.
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	The acquisition of additional stake will be subject to (i) compliance with applicable laws and (ii) approvals from
f)	Indicative time-period for completion of the acquisition;	regulatory authorities in China.

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Pa rel, Mumbai-400 013, India

P +9122 24826000 F +91 22 24826120 W www.cipla .com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

Cipla

g)	Nature of consideration - whether cash consideration or share swap and details of the same;	Conversion of existing shareholder's loan into capital.
h)	Cost of acquisition or the price at which the shares are acquired	USO 16.40 million.
i)	Percentage of shareholding / control acquired and / or number of shares acquired;	Upon completion of acquisition of additional stake, Cipla EU will hold 93.10% stake in the JV Co.
j)	the entity Brief background about acquired in terms of products/line of	Brief background: Please refer (a) above
	of date business acquired, incorporation, history of last 3 years'	Date of Incorporation: 8th August 2019
	turnover, country in which the acquired	History of last 3 years turnover: Nil since the JV Co. is
	entity has any other presence and significant information (in brief)	yet to commence its operations.
		Country: China